Skip to main content

Roche Obtains CE Mark for Cobas HBV Viral Load Test

NEW YORK (GenomeWeb) – Roche today announced its Cobas HBV assay for hepatitis B viral load monitoring has received CE marking.

The assay is a real-time PCR test for HBV genotypes A through H designed for use on the Cobas 6800/8800 systems. The medium- and high-throughput PCR systems were unveiled in 2013, and allow for rapid, automated, mixed-batch processing.

The HBV assay adds to a portfolio of viral load monitoring tests populating these systems, including ones for cytomegalovirus, HIV-1, and hepatitis C virus.

The Cobas 6800/8800 CMV assay was CE marked in December of last year, followed by HIV-1 and HCV. Roche also got CE marks on a series of automated blood screening tests using the platforms. Two of those tests subsequently received an expanded claim for organ donation testing.

The 6800/8800 systems and assays are not currently available in the US, but are commercially available in markets that recognize CE mark.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.